Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
September 12, 2005
- Nippon Chemiphar to Beef Up Generic Business
September 12, 2005
- REGULATORY NEWS IN BRIEF
September 12, 2005
- GSK's New Augmentin Dosage Form, Bayer's Moxifloxacin Recommended for Approval
September 12, 2005
- Pharmacists Should Be Responsible for Supplying GE Drug Info.: Prof. Masuhara
September 12, 2005
- COMMENTARY 4 articles
September 12, 2005
- Mr Matsubara of JPA Calls For Restriction on Long-term Prescriptions
September 12, 2005
- Insurance Premium Must Be Main Financial Resource for Healthcare Services: Seminar
September 5, 2005
- 1st Hyperuricemia/Metabolic Syndrome Forum Stresses Importance of Reduction in Multiple Risk Factors
September 5, 2005
- CDFS Recommends Approval of Candesartan for Chronic Heart Failure
September 5, 2005
- NEW PRODUCTD
September 5, 2005
- Institute Surveys Drug Expenditure Control Measures in 4 Major Countries
September 5, 2005
- PMDA Establishes Study Committee on Clinical Trials
September 5, 2005
- Current Gap Between NHI Prices and Market Prices 7-8%?
September 5, 2005
- NPA Recommends 0.36% Cut in Salary of National Gov't Employees
September 5, 2005
- Long-listed Drugs Should Be Reimbursed According to the Price of Their Generics: MOF
September 5, 2005
- OPINION
September 5, 2005
- Korosho Considers Reflecting Prices, Share of Generics in Prices of Long-listed Drugs
September 5, 2005
- Korosho, Monkasho to Draft New Plan to Promote Clinical Trials
September 5, 2005
- Japan Needs Review System That Meets Its Own Needs: Mr Asonuma
September 5, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…